# ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

> **NCT03402880** · PHASE2 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Extensive Stage Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Epacadostat
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03402880
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled
- **Last updated:** 2018-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402880, "ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03402880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*